Loading
A phase 3 trial of Taletrectinib in non-small-cell lung cancer and small-cell lung cancer, run by Nuvation Bio Inc., now recruiting.
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) is a phase 3 interventional study registered as NCT07154706 by Nuvation Bio Inc., with 180 participants planned, started 2025-08-21 and due to reach its primary completion in 2030-08-30. Interventions recorded: Taletrectinib, Placebo. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Shares Taletrectinib, Nuvation Bio, ROS1-positive non-small-cell lung cancer, Small-cell lung cancer.
Shares Taletrectinib, Nuvation Bio, ROS1-positive non-small-cell lung cancer, Small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares ROS1-positive non-small-cell lung cancer, Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.